Linked Life Data

11985368

Source:http://linkedlifedata.com/resource/pubmed/id/11985368

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
57
pubmed:dateCreated
2002-5-1
pubmed:abstractText
(1) The standard first-line antithrombotic treatment for pulmonary embolism in patients without cardiovascular shock or marked hypotension is intravenous infusion of unfractionated heparin for a few days, followed by several months of oral anticoagulation. (2) In France, tinzaparin is the first low-molecular-weight heparin (LMWH) to be licensed specifically for treating pulmonary embolism (one subcutaneous injection daily). (3) The clinical file mainly comprises data from a comparative unblinded trial versus unfractionated heparin in 612 patients, which shows tinzaparin to have no advantage in terms of overall mortality or the incidence of bleeding. A trial comparing unfractionated heparin with another LMWH, reviparin, gave similar results. (4) In practice, tinzaparin offers the advantage over unfractionated heparin of not requiring intravenous administration. For the least severely ill patients, tinzaparin is an advance. Close laboratory monitoring of clotting factors is warranted for elderly and obese patients, and those with renal impairment. For other patients, intravenous infusion of unfractionated heparin remains the standard treatment for pulmonary embolism.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
T
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1167-7422
pubmed:issnType
Print
pubmed:volume
11
pubmed:owner
HSR
pubmed:pagination
13-5
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Tinzaparin: new indication. Easier treatment of less severe pulmonary embolism.
pubmed:publicationType
Journal Article